Some of these methylation biomarkers have been evaluated with both blood and stool samples for CRC detection but not methylated C9orf50 and methylated KCNQ5. Whereas both methylated C9orf50 and methylated KCNQ5 exhibited good performance for early CRC detection with blood samples with sensitivities of 50.0 and 87.5%, respectively, for stage I CRC (43), their performance with stool samples was lacking. This evidence concerns the gene KCNQ5 and colorectal carcinoma.